Health News: Innovative 干眼症 候选药物 'RCI1001' regains spotlight
韩国 Medical Association News: Additional 疗效 validation for innovative 干眼 候选药物 'RCI1001'
Asia Today: 嘉泉大学吉医院 draws renewed attention to innovative 干眼 候选药物 'RCI1001'
Young Doctors: Professor Kim Dong-hyun demonstrates 疗效 of 干眼 候选药物 'RCI001'
Medical Journal: Gil Hospital re-validates 疗效 of innovative 干眼 候选药物 'RCI1001'
'RCI001,' which inhibits Rac1, a cell signaling molecule, is a 专利ed compound that improves the major symptoms of 干眼症 including 炎症 control, minimal eye irritation, and rapid recovery of 角膜上皮.
Currently, steroid 滴眼液 are used in various 眼表面疾病 including 干眼症治疗药s. Steroid 滴眼液 have excellent 抗炎 effects and provide superior short-term 疗效 compared to other medications, but their long-term use is limited in actual clinical settings due to 副作用 such as increased 眼内压 and cataracts.
In this study, Professor Kim's team confirmed the inhibitory effects of 'RCI001' on 'Rac1' and 'NLRP3 炎性体 (an 炎症-inducing immune protein).' First, topical treatment with 'RCI001' in an immune-overactivated LPS (Lipopolysaccharide) 小鼠模型 confirmed suppression of Rac1 expression and reduction of 炎症 cytokine expression.
In an alkali-induced mouse eye injury model, 'RCI001' showed faster 角膜损伤恢复 compared to conventional steroid formulations. In addition, it demonstrated reduced transcription and protein expression of Rac1 signaling molecules and the 炎症 complex 'NLRP3' in the 角膜 tissue of this model.